Reuters: Health
Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.
Roche enters $1.15 billion licensing deal for Sarepta gene therapy
Roche enters $1.15 billion licensing deal for Sarepta gene therapy
Reuters: Health
Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.
Reuters: Health
Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment